Clinical Trials Sponsored by Immatics US, Inc.

Total 221 results

Immatics US, Inc.

Recruiting

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors (ACTengine)

Cancer | Solid Tumor, Adult | Refractory Cancer | Recurrent Cancer

United States, Germany
Immatics US, Inc.

Completed

TCR-engineered T Cells in Solid Tumors: IMA202-101 (ACTengine)

Cancer | Solid Tumor, Adult | Refractory Cancer | Recurrent Cancer

United States, Germany
Immatics US, Inc.

Completed

Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling

Neoplasms | Adult Solid Tumor | Refractory Cancer | Recurrent Cancer

United States
Immatics US, Inc.

Completed

TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101) (ACTengine)

Cancer | Solid Tumor | Refractory Solid Tumors | Recurrent Solid Tumors

United States, Germany
Immatics US, Inc.
M.D. Anderson Cancer Center

Completed

ACTolog in Patients With Solid Cancers (ACTolog)

Cancer | Solid Tumor

United States
University Hospital, Geneva
Oncovir, Inc.; Immatics Biotechnologies GmbH

Completed

Phase I/II Trial of IMA950 Multi-peptide Vaccine Plus Poly-ICLC in Glioblastoma

CNS Tumor, Adult

Switzerland
Optinose US Inc.

Terminated

A Study to Evaluate Change in Viral Load After OPN-019 in Adults With COVID-19

Covid19

Mexico
Optinose US Inc.

Completed

12-Month OL Intranasal Fluticasone Propionate BID Using OptiNose Device

Nasal Polyps

United States
Optinose US Inc.

Completed

A Study to Compare the Bioavailability Intranasal Administration of 200 and 400 µg or 400 µg Alone of OPTINOSE™ FLUTICASONE With 440 µg of Flovent® HFA (Fluticasone Propionate) Inhalation Aerosol (Part 2)

Mild to Moderate Asthma

Ireland
Optinose US Inc.

Completed

Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis Without the Presence of Nasal Polyps

Chronic Rhinosinusitis

United States, Australia, Poland, New Zealand, Spain, Georgia, United Kingdom, Bulgaria, Czechia, Romania
US Biotest, Inc.

Terminated

Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19

SARS-CoV-2 Infection | Respiratory Distress Syndrome, Adult | Adult Respiratory Distress Syndrome | COVID-19 Virus Infection | SARS Coronavirus 2 Infection | 2019 Novel Coronavirus Infection

United States
Optinose US Inc.

Completed

Efficacy & Safety of OPN-375 Adults With Bilateral Nasal Polyps Using Nasoendoscopic Video

Nasal Polyposis

United States
Optinose US Inc.

Completed

Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety

Bilateral Nasal Polyposis

United States, Canada
CellAegis US, Inc.

Unknown

Remote Ischemic Conditioning Using the autoRIC (SHIELD)

Ischemia-Reperfusion Injury

Canada, United States
Optinose US Inc.

Completed

Study Evaluating the Safety of Intranasal Administration of 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Chronic Sinusitis With or Without Nasal Polyps

Chronic Sinusitis With or Without Nasal Polyps

United States
Optinose US Inc.

Completed

Safety & Efficacy of a Single Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine

Migraine Headache

United States
Optinose US Inc.

Recruiting

OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps

Bilateral Nasal Polyposis

United States
Optinose US Inc.

Completed

Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis With or Without the Presence of Nasal Polyps

Chronic Rhinosinusitis

United States, United Kingdom, Bulgaria, Canada, Georgia, Poland, Russian Federation, Sweden
Optinose US Inc.

Completed

Efficacy and Safety Study of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Using a Novel Bi-directional Device

Bilateral Nasal Polyposis

United States
Optinose US Inc.

Completed

Bioavailability Study to Compare OPTINOSE SUMATRIPTAN With IMITREX® in Healthy Subjects

Migraine

United States
Us Helping Us, People Into Living, Inc.

Not yet recruiting

Predictors of Health Service Utilizations Among Key Population in Washington DC

HIV | Health Behavior | Pre-exposure Prophylaxis
Us Helping Us, People Into Living, Inc.

Recruiting

SNS and PrEP Initiation and Adherence in Black SMM

HIV

United States
Spectral Diagnostics (US) Inc.

Recruiting

Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study (TIGRIS)

Septic Shock | Endotoxemia

United States
RVAC Medicines (US), Inc.

Terminated

Safety and Immunogenicity of RVM-V001 in Healthy Individuals Previously Vaccinated With BNT162b2 and mRNA-1273

COVID-19 | Infectious Disease

Australia
RVAC Medicines (US), Inc.

Terminated

Safety & Immunogenicity of RVM-V001/RVM-V002 or RVMV001+RVMV002 (Co Administered as Separate Injections) in Healthy Individuals

COVID-19 | Infectious Disease

Singapore
Harbour BioMed US, Inc.

Completed

A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of a Study Drug in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

Australia, China, Hong Kong
Spectral Diagnostics (US) Inc.

No longer available

Evaluating the Use of Polymyxin B Cartridge Hemoperfusion for Patients With Septic Shock and COVID 19

Septic Shock | Endotoxemia | COVID | Corona Virus Infection | Sepsis, Severe

United States
Harbour BioMed US, Inc.

Not yet recruiting

A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of HBM1020 in Subjects With Advanced Solid Tumors

Advanced Solid Tumor
US Endoscopy Group Inc.

Active, not recruiting

trūFreeze® Palliative Esophageal Cancer

Esophageal Cancer

United States
US Endoscopy Group Inc.

Completed

trūFreeze® Spray Cryotherapy Patient Registry

Barrett Esophagus | Esophageal Neoplasm | Esophageal Stenosis | Esophageal Dysplasia | Bronchial Neoplasm | Stenosis of Bronchus or Trachea

United States
Spectral Diagnostics (US) Inc.

Temporarily not available

Open-label Evaluation of Polymyxin B Hemoperfusion for Septic Shock (EUPHORIA)

Septic Shock | Endotoxemia
Spectral Diagnostics (US) Inc.

Completed

Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Septic Shock (EUPHRATES)

Septic Shock | Endotoxemia

United States, Canada
BioNTech US Inc.

Recruiting

NEO-PTC-01 in Patients With Advanced or Metastatic Melanoma

Metastatic Melanoma | Unresectable Melanoma

Belgium, Netherlands, Spain
NanOlogy, LLC
US Biotest, Inc.

Available

Expanded Access to NanoDoce

Urogenital Neoplasms
NanOlogy, LLC
US Biotest, Inc.

Completed

Evaluation of NanoDoce® in Participants With Urothelial Carcinoma

Urologic Neoplasms | Urogenital Neoplasms | Urinary Bladder Cancer | Bladder Cancer | Urothelial Carcinoma | Urologic Cancer | Urinary Bladder Neoplasm | Cancer of the Bladder | Malignant Tumor of the Urinary Bladder

United States
NanOlogy, LLC
US Biotest, Inc.

Active, not recruiting

Trial of NanoPac Intratumoral Injection in Lung Cancer

Lung Cancer | Lung Cancer, Nonsmall Cell | Neoplasm of Lung | Lung Cancer, Small Cell

United States
NanOlogy, LLC
US Biotest, Inc.

Completed

Intracystic Injection of NanoPac® in Subjects With Mucinous Cystic Pancreatic Neoplasms

Pancreatic Mucinous-Cystic Neoplasm

United States
NanOlogy, LLC
US Biotest, Inc.

Terminated

Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer

Ovarian Carcinoma

United States
NanOlogy, LLC
US Biotest, Inc.

Completed

Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer

Adenocarcinoma of the Prostate

United States
US Oncology Research
Quintiles, Inc.

Completed

Biomarker Analysis for Patients With Metastatic Colorectal Cancer (MCC)

Colorectal Neoplasms | Advanced Metastatic Colorectal Cancer

United States
NanOlogy, LLC
US Biotest, Inc.

Available

Expanded Access to NanoPac
NanOlogy, LLC
US Biotest, Inc.

Completed

Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma

Locally Advanced Pancreatic Adenocarcinoma

United States
NanOlogy, LLC
US Biotest, Inc.

Terminated

Trial of NanoPac Focal Therapy for Prostate Cancer

Urogenital Neoplasms | Genital Neoplasms, Male | Prostate Cancer | Prostate Adenocarcinoma | Prostatic Neoplasm | Localized Cancer | Prostate Cancer Adenocarcinoma

United States
NanOlogy, LLC
US Biotest, Inc.

Withdrawn

Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma

Kidney Cancer | Renal Cell Carcinoma | Renal Cell Cancer | Adenocarcinoma of Kidney | Adenocarcinoma, Renal
US Oncology Research
Genentech, Inc.

Terminated

Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer

Breast Neoplasms | Malignant Tumor of the Breast

United States
NanOlogy, LLC
US Biotest, Inc.

Completed

Study of Topical SOR007 Ointment for Cutaneous Metastases

Cutaneous Metastasis

United States
US Biotest, Inc.
Tarix Pharmaceuticals

Terminated

Safety Study of TXA127 to Elevate CD4+ T-Lymphocyte Counts in HIV-Infected Patients on Stable HAART Therapy

HIV Infections

United States
Millendo Therapeutics US, Inc.

Terminated

Nevanimibe HCl for the Treatment of Classic CAH

Congenital Adrenal Hyperplasia

Spain, Israel, France, Brazil, Czechia
Astellas Pharma Inc
Astellas Pharma US, Inc.

Terminated

A Randomized Study to Evaluate FK962 in Subjects With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

United States, Canada
Astellas Pharma Inc
Astellas Pharma US, Inc.

Completed

A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma

Melanoma

United States

Clinical Trials Sponsored by Immatics US, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations